AB1216 SYMPTOMATIC SLOW-ACTING DRUGS FOR GONARTHROSIS: BETWEEN EXPECTATIONS AND REALITY

Background Osteoarthritis of the knee is most common cause chronic pain and disability in patients. In addition to non-steroidal anti-inflammatory drugs analgesics, symptomatic slow-acting anti-arthritic (SAALs) define a specific class medications used treatment osteoarthritis knee. With delayed effect, this family reduce intensity functional discomfort caused by destruction cartilage. Objectives The objective study was evaluate fears expectations patients before response as well degree satisfaction after one year treatment. Methods This conducted form an individual questionnaire, 56 followed consultation for primary gonarthrosis without period congestive attack, diagnosis made radiography according classification Kellgren Lawrence, any patient with secondary or very disabling excluded. Patients were questioned about their start An evaluation therapeutic done different parameters: visual analogue scale (VAS pain), Lequesne index knee, decrease analgesic consumption, improvement walking perimeter side effects reduction. Global evaluated likert composed 7 degrees (from extremely satisfied dissatisfied). Results We included patients, average age 44 years, female sex represented 59%, educational level 20%. According stage 2 represents (40%), 3 (52%) 4 (8%). There 30% on chondroitin-based antiarthritis drugs, 60% glucosamine 10% avocado-soybean unsaponifiable extract. VAS 5 ± 1.1, (knee) 7. Fear exacerbation noted 15%, 20% afraid handicap 49% probable surgery, 16% had no fear. Before initiation treatment, 65% hoped function, feared surgery 35% thought it placebo. mean 3±2.2 vs ±1.1 (p= 0.003), 4.9 statistically significant difference gait 51%, 41% reported reduction consumption 3% such nausea vomiting. After 1 45% 15% dissatisfied, not satisfied. Conclusion Patient are important components quality care. new approach guarantee adherence. REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.